Event: Tuesday, August 4, 2026, before market open; earnings call at 7:30 a.m. ET. (ir.revvity.com)
Revvity enters Q2 with a cleaner narrative than it had a quarter ago: improving underlying demand in Life Sciences, sustained strength in reproductive health, and a planned exit from China immunodiagnostics that removes a structurally pressured, lower-margin business from the go-forward framework.
The setup is therefore less about a headline EPS beat and more about whether Q2 validates three assertions management made in May:
Management’s own Q2 framework is for 2%–3% pro forma organic growth, $699 million–$707 million of pro forma revenue, roughly 27% pro forma adjusted operating margin, and adjusted EPS equal to about 23% of full-year guidance—or approximately $1.20–$1.22 based on the $5.20–$5.30 full-year range. That outlook intentionally excludes the China immunodiagnostics business slated for divestiture.
| Area | What investors should look for | Why it matters |
|---|---|---|
| Organic growth | Delivery at or above the 2%–3% pro forma organic-growth outlook | Establishes whether Q1’s 6% pro forma growth was a one-off strong quarter or the start of a broader recovery. |
| Life Sciences demand | Low-single-digit growth in Life Science Solutions and evidence that instruments/reagents remain positive | This is the key cyclical variable: pharma/biotech and academic budgets had been weak, so continued improvement would support a higher 2027 earnings base. |
| Software cadence | A likely sharp organic decline in Q2 due to difficult comparison and contract timing, alongside continued SaaS/ARR and pipeline progress | Investors should not overreact to reported software growth alone; bookings and annualized portfolio value are more useful indicators of the medium-term opportunity. |
| Diagnostics | Mid- to high-single-digit growth, led by reproductive health; performance of immunodiagnostics ex-China | This segment provided the strongest Q1 growth and is central to offsetting a softer software quarter. |
| Margins | Ability to reach ~27% pro forma adjusted operating margin | The quarter should show the early benefit of seasonal volume, FX, and productivity actions; more meaningful cost-action impact is expected in 2H. |
| 2026 guidance | Reaffirmation or raise of $2.81B–$2.84B revenue, 3%–4% pro forma organic growth, and $5.20–$5.30 adjusted EPS | With the stock higher into the print, unchanged guidance may be adequate, but a raise would require better confidence in end-market improvement. |
Q1 reported revenue was $711 million, up 7% year over year, with 3% organic growth. On the pro forma basis excluding China immunodiagnostics, revenue was $687 million, organic growth was 6%, adjusted operating margin was 24.0%, and adjusted EPS was $1.04. (ir.revvity.com)
The segment read-through was constructive:
The important caveat: Q1 had an extra fiscal week and strong reproductive-health performance, while Q2 has a difficult software comparison. That is why management’s Q2 organic-growth outlook steps down to 2%–3%.
The investment case rests on Revvity being more exposed to novel science and preclinical validation workflows than to commoditized life-science tools. The company has argued that higher-content screening, automation, liquid handling, reagents, and scientific software could benefit as AI increases the number of therapeutic hypotheses that must be validated in wet labs.
There are tangible early signals supporting that thesis: management discussed strength in high-content screening, broader improvement in certain instrument categories, and positive growth from both pharma/biotech and academic customers in Q1. But the company has also retained a conservative full-year outlook, implying it has not yet underwritten a broad-based tools-market recovery.
For Q2, the highest-quality outcome would be:
Reproductive health remains the most important operating bright spot. In Q1, the business grew double digits organically, supported by newborn screening, instrument placements, and Genomics England sample volumes. Diagnostics overall posted 9% pro forma organic growth, although reported segment margin still declined year over year due to mix, FX, tariffs, and the extra fiscal week. (ir.revvity.com)
For Q2, investors should watch whether:
A moderation in reproductive-health growth would not necessarily break the thesis, but it would raise the burden on Life Sciences to support the full-year growth outlook.
The proposed divestiture of China immunodiagnostics is strategically central. The business represented roughly 6% of 2025 revenue, and Revvity has shifted its forward guidance to a pro forma basis excluding it. Management expects the divestiture to close in 2027, subject to a definitive agreement and regulatory approvals. (ir.revvity.com)
The trade-off is clear:
The August report should provide an update on whether a definitive agreement was signed during Q2, as management had targeted. Any delay, changed economics, or additional transition costs would likely become a focal point.
The Q1 filing showed that tariffs, product mix, FX, and the extra fiscal week drove a 200-basis-point decline in reported gross margin. Tariffs alone raised Q1 cost of revenue by about $8 million, with an estimated net gross-margin impact of roughly $6 million after mitigation actions. (sec.gov)
Management’s margin plan relies on cost actions—including workforce reductions, facility consolidation, sourcing, and operational initiatives—that are intended to be completed around midyear. Q1 restructuring actions affected roughly 2% of the workforce, indicating that the program is already underway. (sec.gov)
Capital allocation is also constructive:
RVTY closed at $115.25 on August 3, up about 19% year to date from the December 31, 2025 close. At that price and the midpoint of management’s $5.20–$5.30 adjusted-EPS outlook, the shares trade at roughly 22x 2026 guided adjusted EPS.
That means the market appears to be giving Revvity partial credit for a cleaner portfolio, eventual margin expansion, and a recovery in core end markets. It likely still needs proof—not just promise—on organic-growth durability and 2H operating leverage.
RVTY’s Q2 report is a validation quarter. The company does not need a dramatic headline beat to support the thesis; it needs to demonstrate that Q1’s improving core trends were repeatable, that Diagnostics remains a dependable growth engine, and that margins are set to inflect as cost initiatives land.
A result around the company’s Q2 framework with firm full-year guidance would keep the recovery narrative intact. A beat driven by Life Sciences demand and accompanied by a stronger second-half outlook could be more meaningful, because it would begin to validate the longer-term case for higher growth and better incremental margins.